Phathom Pharmaceuticals (PHAT) Projected to Post Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is projected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $57.4440 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Stock Performance

Shares of NASDAQ:PHAT opened at $11.61 on Wednesday. Phathom Pharmaceuticals has a 52-week low of $2.21 and a 52-week high of $18.31. The company has a market capitalization of $829.19 million, a PE ratio of -3.04 and a beta of 0.51. The company has a fifty day moving average of $14.52 and a 200-day moving average of $13.46.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Fox Run Management L.L.C. acquired a new stake in shares of Phathom Pharmaceuticals during the fourth quarter worth $340,000. Brevan Howard Capital Management LP bought a new stake in Phathom Pharmaceuticals during the second quarter valued at $267,000. Virtu Financial LLC bought a new stake in Phathom Pharmaceuticals during the fourth quarter valued at $258,000. Rafferty Asset Management LLC acquired a new stake in Phathom Pharmaceuticals during the 4th quarter worth about $230,000. Finally, Graham Capital Management L.P. bought a new position in shares of Phathom Pharmaceuticals in the 4th quarter worth about $213,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on PHAT shares. Raymond James Financial started coverage on Phathom Pharmaceuticals in a research report on Thursday, December 11th. They issued a “strong-buy” rating and a $28.00 target price for the company. HC Wainwright upped their price objective on Phathom Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, January 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Thursday, January 22nd. Finally, Barclays began coverage on shares of Phathom Pharmaceuticals in a research note on Monday, December 8th. They set an “equal weight” rating and a $16.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.71.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.